4.3 Review

The science and practice of lithium therapy

期刊

出版社

SAGE PUBLICATIONS LTD
DOI: 10.1177/0004867412437346

关键词

Bipolar disorder; lithium; mood stabilizer; neuroprotection; suicide

资金

  1. AstraZeneca
  2. Eli Lilly
  3. Organon
  4. Pfizer
  5. Servier
  6. Wyeth
  7. Medical Benefits Fund of Australia
  8. Bristol-Myers Squibb
  9. GlaxoSmithKline
  10. Novartis
  11. Mayne Pharma

向作者/读者索取更多资源

Introduction: Despite more that 60 years of clinical experience, the effective use of lithium for the treatment of mood disorder, in particular bipolarity, is in danger of becoming obsolete. In part, this is because of exaggerated fears surrounding lithium toxicity, acute and long-term tolerability and the encumbrance of life-long plasma monitoring. Recent research has once again positioned lithium centre stage and amplified the importance of understanding its science and how this translates to clinical practice. Objective: The aim of this paper is to provide a sound knowledge base as regards the science and practice of lithium therapy. Method: A comprehensive literature search using electronic databases was conducted along with a detailed review of articles known to the authors pertaining to the use of lithium. Studies were limited to English publications and those dealing with the management of psychiatric disorders in humans. The literature was synthesized and organized according to relevance to clinical practice and understanding. Results: Lithium has simple pharmacokinetics that require regular dosing and monitoring. Its mechanisms of action are complex and its effects are multi-faceted, extending beyond mood stability to neuroprotective and anti-suicidal properties. Its use in bipolar disorder is under-appreciated, particularly as it has the best evidence for prophylaxis, qualifying it perhaps as the only true mood stabilizer currently available. In practice, its risks and tolerability are exaggerated and can be readily minimized with knowledge of its clinical profile and judicious application. Conclusion: Lithium is a safe and effective agent that should, whenever indicated, be used first-line for the treatment of bipolar disorder. A better understanding of its science alongside strategic management of its plasma levels will ensure both wider utility and improved outcomes.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Neurosciences

Nutrition and bipolar disorder: a systematic review

Fernanda C. Gabriel, Manoela Oliveira, Michael Berk, Elisa Brietzke, Felice N. Jacka, Beny Lafer

Summary: This review aims to summarize the relationship between nutrition and bipolar disorder (BD). Findings suggest that the intake of unsaturated fatty acids, seafood, folic acid, and zinc is associated with improved BD symptoms. The impacts of creatine, carnitine, vitamin D, inositol, or NAC supplementation on BD are variable and mainly non-significant. Promising results are associated with Coenzyme Q10 (Coq10) and probiotics. Overall, dietetic approaches might be included as part of BD treatment, and individuals with BD should choose healthy dietary lifestyles.

NUTRITIONAL NEUROSCIENCE (2023)

Article Psychiatry

Depression, anxiety and worry in young Pacific adults in New Zealand during the COVID-19 pandemic

Richard J. Siegert, Ajit Narayanan, Joanna Dipnall, Lisa Gossage, Wendy Wrapson, Alexander Sumich, Fabrice Merien, Michael Berk, Janis Paterson, El-Shadan Tautolo

Summary: This study examined the symptoms of anxiety, depression, and hopelessness among young Pacific adults living in Auckland, New Zealand during the 2020/2021 COVID-19 pandemic and identified potential protective factors. The findings showed that approximately 25% of the participants scored in the moderate to severe range for anxiety, and 10% for depression. Additionally, around 40% of the sample reported finding the first lockdown very stressful. Self-compassion and Pacific Identity were moderately negatively correlated with anxiety, depression, hopelessness, and perceived stress.

AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2023)

Article Psychiatry

Personality traits as mediators of the relationship between childhood trauma and depression severity in bipolar disorder: A structural equation model

Anna L. Wrobel, Samantha E. Russell, Anuradhi Jayasinghe, Bianca E. Kavanagh, Mojtaba Lotfaliany, Alyna Turner, Olivia M. Dean, Sue M. Cotton, Claudia Diaz-Byrd, Anastasia K. Yocum, Elizabeth R. Duval, Tobin J. Ehrlich, David F. Marshall, Michael Berk, Melvin G. McInnis

Summary: This study found that personality traits may mediate the relationship between childhood trauma and the severity of bipolar depression; the indirect effect through neuroticism was significant in the mediation model. The results suggest that an individual's personality structure is an important factor to consider in therapeutic plans for individuals with bipolar disorder who have a history of childhood trauma.

AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2023)

Review Clinical Neurology

The concept of metabolic jet lag in the pathophysiology of bipolar disorder: implications for research and clinical care

Elena Koning, Alexandra McDonald, Alexander Bambokian, Fabiano A. Gomes, Jacob Vorstman, Michael Berk, Jennifer Fabe, Roger S. McIntyre, Roumen Milev, Rodrigo B. Mansur, Elisa Brietzke

Summary: Bipolar disorder (BD) is a chronic mental disorder characterized by depressive and manic episodes, circadian rhythm disruption, and changes in energetic metabolism. Metabolic jet lag is considered a core component of BD pathophysiology, associated with irregular eating rhythms and circadian desynchronization of energetic metabolism.

CNS SPECTRUMS (2023)

Review Psychiatry

A systematic review of interventions in the early course of bipolar disorder I or II: a report of the International Society for Bipolar Disorders Taskforce on early intervention

A. Ratheesh, D. Hett, J. Ramain, E. Wong, L. Berk, P. Conus, M. A. Fristad, T. Goldstein, M. Hillegers, S. Jauhar, L. Kessing, D. J. Miklowitz, G. Murray, J. Scott, M. Tohen, L. N. Yatham, A. H. Young, M. Berk, S. Marwaha

Summary: This systematic review examined the effectiveness of interventions in the early course of bipolar disorder (BD). The findings suggested that lithium use was associated with lower recurrence risk compared to other mood stabilizers, and mood stabilizers were associated with better global functioning compared to antipsychotics in the medium term. Psychological interventions, such as family-focused and cognitive-behavioral interventions, were associated with reduced recurrence risk or improved symptomatic outcomes. Pharmacological interventions were more efficacious when utilized in the earlier stages of illness.

INTERNATIONAL JOURNAL OF BIPOLAR DISORDERS (2023)

Article Psychiatry

Anxiety disorders are associated with reduced bone mineral density in men: Findings from the Geelong Osteoporosis Study

Gregory Roebuck, Michael Mazzolini, Mohammadreza Mohebbi, Julie A. A. Pasco, Amanda L. L. Stuart, Malcolm Forbes, Michael Berk, Lana Williams

Summary: This study investigated the effect of anxiety disorders on bone mineral density (BMD) and found a significant association between anxiety disorders and reduced BMD in men, which may be mediated by comorbid mood disorders.

ACTA PSYCHIATRICA SCANDINAVICA (2023)

Article Substance Abuse

How does a family history of psychosis influence the risk of methamphetamine-related psychotic symptoms: Evidence from longitudinal panel data

Rebecca McKetin, Philip J. Clare, David Castle, Alyna Turner, Peter J. Kelly, Dan I. Lubman, Shalini Arunogiri, Victoria Manning, Michael Berk

Summary: This study aimed to determine whether the risk of psychotic symptoms during methamphetamine use was dependent on, increased by, or independent of having a family history of psychosis. The findings showed that both methamphetamine use and family history of psychosis were independently associated with psychotic symptoms in the past week, and the joint risk was even larger when they occurred together. There was no significant interaction between family history of psychosis and methamphetamine use in predicting psychotic symptoms, but family history of psychosis was an independent risk factor for the absolute risk of psychotic symptoms in this population.

ADDICTION (2023)

Editorial Material Geriatrics & Gerontology

Brain Health Is a Determinant of Mental Health

Harris A. Eyre, Robert Lundin, Veronica Podence Falcao, Michael Berk, Tadeusz Hawrot, Marion Leboyer, Frederic Destrebecq, Zoltan Sarnyai, Charles Reynolds, Helen Lavretsky, Kavitha Kolappa, Jeffrey Cummings

AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2023)

Article Psychiatry

Effects of risperidone/paliperidone versus placebo on cognitive functioning over the first 6 months of treatment for psychotic disorder: secondary analysis of a triple-blind randomised clinical trial

Kelly Allott, Hok Pan Yuen, Lara Baldwin, Brian O'Donoghue, Alex Fornito, Sidhant Chopra, Barnaby Nelson, Jessica Graham, Melissa J. J. Kerr, Tina-Marie Proffitt, Aswin Ratheesh, Mario Alvarez-Jimenez, Susy Harrigan, Ellie Brown, Andrew D. D. Thompson, Christos Pantelis, Michael Berk, Patrick D. D. McGorry, Shona M. M. Francey, Stephen J. J. Wood

Summary: The drivers of cognitive change following first-episode psychosis are not well understood. This study conducted a secondary analysis of a randomized, triple-blind, placebo-controlled trial to investigate the role of antipsychotic medication on cognitive performance in patients with first-episode psychotic disorder. The results showed that the medication group exhibited decline in verbal learning and memory, while the placebo group showed improvement.

TRANSLATIONAL PSYCHIATRY (2023)

Article Pharmacology & Pharmacy

Oxycodone-induced dopaminergic and respiratory effects are modulated by deep brain stimulation

Jason Yuen, Abhinav Goyal, Aaron E. Rusheen, Abbas Z. Kouzani, Michael Berk, Jee Hyun Kim, Susannah J. Tye, Osama A. Abulseoud, Tyler S. Oesterle, Charles D. Blaha, Kevin E. Bennet, Kendall H. Lee, Yoonbae Oh, Hojin Shin

Summary: Opioids are the leading cause of overdose death in the United States, with nearly 70,000 deaths in 2020. Deep brain stimulation (DBS) is a promising treatment for substance use disorders. This study investigated the modulation of dopaminergic and respiratory effects of oxycodone by DBS of the ventral segmental area (VTA) in rodents. The results demonstrated that DBS reduced baseline dopamine levels and alleviated the increase in dopamine levels and respiratory depression induced by oxycodone.

FRONTIERS IN PHARMACOLOGY (2023)

Review Biochemistry & Molecular Biology

CaMKK2 as an emerging treatment target for bipolar disorder

Jacqueline Kaiser, Kevin Nay, Christopher R. Horne, Luke M. Mcaloon, Oliver K. Fuller, Abbey G. Muller, Douglas G. Whyte, Anthony R. Means, Ken Walder, Michael Berk, Anthony J. Hannan, James M. Murphy, Mark A. Febbraio, Andrew L. Gundlach, John W. Scott

Summary: Current pharmacological treatments for bipolar disorder are inadequate and lack revolutionary therapies due to limited efficacy, burdensome side-effects, and a poor understanding of the underlying disease mechanisms. Targeting the CaMKK2 enzyme shows promise as a new treatment strategy for bipolar disorder, as it is associated with the disease and its behaviors can be ameliorated by increasing CaMKK2 activity with lithium.

MOLECULAR PSYCHIATRY (2023)

Review Biochemistry & Molecular Biology

Metabolic regulation to treat bipolar depression: mechanisms and targeting by trimetazidine

Sourav Khanra, Preethi Reddy, Anna Gimenez-Palomo, Chun Hui J. Park, Bruna Panizzutti, Madeleine McCallum, Shyam Sundar Arumugham, Shreekantiah Umesh, Monojit Debnath, Basudeb Das, Ganesan Venkatasubramanian, Melanie Ashton, Alyna Turner, Olivia M. Dean, Ken Walder, Eduard Vieta, Lakshmi N. Yatham, Isabella Pacchiarotti, Y. C. Janardhan Reddy, Nishant Goyal, Muralidharan Kesavan, Lluc Colomer, Michael Berk, Jee Hyun Kim

Summary: The core feature of bipolar disorder is pathological disturbances in mood, along with disrupted thinking and behavior. Due to its complex and heterogeneous etiology, a range of genetic and environmental factors are involved. This complexity and poorly understood neurobiology make it challenging to develop drugs, resulting in limited treatment options, especially for bipolar depression. Therefore, novel approaches are needed, such as investigating the potential of trimetazidine as a treatment option for bipolar depression.

MOLECULAR PSYCHIATRY (2023)

Article Psychiatry

An Expert Roundtable Discussion on the Use of Classic Monoamine Oxidase Inhibitors in the Treatment of Depression-Part Two

Michael Berk, Vincent Van den Eynde, Karthikeyan Ganapathy, Chittaranjan Andrade, Tom Birkenhager, J. Alexander Bodkin, David Nutt, Brian Barnett, Simeon Shalom Feinberg, Gordon Parker, Eric Ruhe, Michele Fornaro, Charles Redhead, Lila Godet, Peter Kenneth Gillman

Summary: Experienced clinicians and academics from the International MAOI Expert Group provide comments on the use of monoamine oxidase inhibitor (MAOI) pharmacotherapy for depression. They emphasize the importance of good pharmacological practice, starting with a low dose and making changes slowly and gradually. The comments also discuss issues related to augmentation and drug combinations, and highlight the unique ability of MAOIs to improve dopamine function.

PSYCHIATRIC ANNALS (2023)

Meeting Abstract Clinical Neurology

Diet, nutrition, and eating behaviors in bipolar disorder: A narrative review from the ISBD nutrition and exercise task force (NEXT)

Elisa Brietzke, Elena Koning, Mohammad Alsuwaidan, Vicent Balanza-Martinez, Michael Berk, Jess Fiedorowicz, Mark Frye, Manuel Gardea-Resendez, Fabiano Gomes, Ana Gonzalez-Pinto, Rodrigo Mansur, Wolfgang Marx, Roumen Milev, Lucas Neves, Andrew Nierenberg, Andrew Olagunju, Gayatri Saraf, Marco Solmi, Beny Lafer

BIPOLAR DISORDERS (2023)

Meeting Abstract Clinical Neurology

Nutrition and bipolar disorder: A systematic review

Fernanda Carramaschi Gabriel, Michael Berk, Elisa Brietzke, Felice Jacka, Beny Lafer

BIPOLAR DISORDERS (2023)

暂无数据